Log inSign up
Gregg Fonarow MD
11.9K posts
Gregg Fonarow MD profile banner
@gcfmd

Gregg Fonarow MD

@gcfmd
Los Angeles, CA
Joined December 2012
180
Following
12.5K
Followers
RepliesRepliesRepostsRepostsMediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
  • @gcfmd
    Gregg Fonarow MD
    @gcfmd
    15h
    🫀 The 4 pillars of #HFrEF therapy don't overlap….they STACK ARNI + BB + MRA + SGLT2i vs no meds:
 📉 ~61% ↓ death (HR 0.39)
 ➕ +6 life-years (vs ACEI+BB) Distinct pathways = additive benefit Not hype: 2 independent meta-analyses agree (Tromp 0.39 ≈ Vaduganathan 0.38)
    Image
    Steve Greene and 9 others
    3
  • @gcfmd
    Gregg Fonarow MD
    @gcfmd
    Sep 8
    💊 4 foundational HFrEF therapies PROVEN to prolong life & ⬇️ HF 🏨s Yet, only 18% of eligible patients get all 4 Closing that gap could prevent 113,747 deaths/year 357,332 HF hospitalizations/year Implement what works! 🫀#HeartFailure
    Image
    Steve Greene and 9 others
    2
  • @gcfmd
    Gregg Fonarow MD
    @gcfmd
    Sep 7
    Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation statnews.com/2026/09/07/nov… The company said it had halted the HERMES and ATHENA trials of its drug, ziltivekimab, after a DSMB found they were unlikely to succeed Investigators were informed Friday
    Image
    Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
    From statnews.com
    3
  • @gcfmd
    Gregg Fonarow MD
    @gcfmd
    Sep 6
    Milton Packer's HFpEF thesis in @JACCJournals (104 pages long): preserved-EF HF is driven primarily by excess & dysfunctional adipose tissue and its adipokines Hypertension, diabetes & metabolic syndrome largely downstream, not independent causes
    Image
    The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to...
    From jacc.org
    5
  • @gcfmd
    Gregg Fonarow MD
    @gcfmd
    Sep 5
    First-in-class, novel-mechanism agents tested in Phase 3 CV outcomes trials have <20% success rate It is very challenging to incrementally/meaningfully improve CV outcomes Yet, tragic when there are proven therapies, but not implemented, and preventable events allowed to occur
    Image
    Adrian “WE NEED RCTS!” Hernandez and 8 others
    8
Advertisement
Advertisement